BIC/FTC/TAF Safe and Efficacious in Women and Girls Across 5 Phase II/III Clinical Trials

IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
In pooled analysis of 373 treatment-naive and virologically suppressed females, no emergent resistance or discontinuation for renal or bone adverse events was observed.
Format: Microsoft PowerPoint (.ppt)
File Size: 269 KB
Released: November 20, 2019

Acknowledgements

Provided by USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Understand medical, social, and emotional challenges faced by older PWH, from Clinical Care Options (CCO)

Jonathan Appelbaum, MD, FACP, AAHIVS
Program Director
Melanie Reese
Program Director
Lydia Mungherera, MBChB Cristina Mussini, MD Dorothy Onyango Marc Thompson
Released: August 9, 2022

Clinical Care Options (CCO) presents patient advocate and patient discussing the importance of overcoming local barriers to HIV care for women

person default Angelina Namiba Released: August 5, 2022

Safety and efficacy of broadly neutralizing antibody VRC01 with early ART in infants with HIV, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

ANDES: Wk 48 safety and efficacy of generic darunavir/ritonavir + lamivudine for initial HIV treatment, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings